Signe Baldere-Sildedze, a member of the board of the drug manufacturer JSC “Olainfarm”, has acquired the right to represent the company separately, according to “Firmas.lv” information. Until now, Baldere-Sildedze had the right to represent the company together with at least two other board members.
–
Chairman of the Board Jerūnas Veitesas and members of the Board Elena Bušberga and Zane Kotāne also have the right to represent the company separately on the Board of Olainfarm, while member of the Board Raimonds Terentjevs has the right to represent the company together with at least two other members of the Board.
Changes in the right of representation in the Register of Enterprises were registered on Monday, May 17.
It has already been reported that the turnover of the Olainfarm group last year was 122.157 million euros, which is 11% less than in 2019, while the group’s profit decreased 2.3 times and was 9.478 million euros.
Olainfarm manufactures finished dosage forms, pharmaceuticals and food supplements, as well as chemicals and active pharmaceutical ingredients. The largest shareholder of Olainfarm is Olmafarm (42.56%), which is owned in equal shares by Valerija Maligina’s heirs: Irina Maligina, Anna Emilija Maligina and Nika Savelyeva. Olainfarm shares are listed on the official list of Nasdaq Riga.
– .
